GLP-1 receptor agonists and breast cancer: metabolic insights and clinical implications
Become a member today
It remains unclear whether the benefits of pharmacological or non-pharmacological therapies in obese HFpEF patients are attributable solely to weight loss or are also directly mediated by weight loss-independent effects on cardiovascular structure, function, and hemodynamics
G., Villaschi, S., Palmieri, G., Corsi, M., and Maccari, F
This is because: GLP-1 agonists: Slow gastric emptying, enhance insulin secretion, regulate hepatic glucose Amylin agonists: Suppress appetite centrally, slow gastric emptying via distinct pathways Together: Complementary mechanisms produce additive/synergistic effects on weight loss Cagrilintide Monotherapy Trials Initial clinical development focused on establishing the safety, tolerability, and efficacy of cagrilintide as a standalone therapy for weight management